SAN ANTONIO – Compared with a treatment of the physician’s choice, the antibody-drug conjugate trastuzumab emtansine (T-DM1) prolongs median overall survival by almost 7 months among women with heavily pretreated HER2-positive metastatic breast cancer, according to new data from the TH3RESA trial.
In an interview at the San Antonio Breast Cancer Symposium, Dr. Hans Wildiers, professor at Katholieke Universiteit Leuven, Belgium, discusses the findings and how they further solidify the role of T-DM1 in the treatment of advanced HER2-positive disease.